Effect of formaldehyde inactivation on poliovirus

Journal of Virology

Volumn 88, Issue 20, 2014, Pages 11955-11964

  Wilton, Thomas ^a   Dunn, Glynis ^a   Eastwood, David ^a   Minor, Philip D ^a   Martin, Javier ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FORMALDEHYDE; HUMAN POLIOVIRUS RECEPTOR; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VIRUS RNA;

ANTIGENICITY; ARTICLE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE AMPLIFICATION; GENETIC TRANSFECTION; HIGH TEMPERATURE; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; POLIOMYELITIS VIRUS; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; ULTRACENTRIFUGATION; VIRUS INACTIVATION; VIRUS RESISTANCE; CELL LINE; DRUG EFFECTS; GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE; FLOW CYTOMETRY; FORMALDEHYDE; HUMANS; POLIOVIRUS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, VIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 84907907786     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01809-14     Document Type: Article

References (64)

1. Dowdle WR, Featherstone DA, Birmingham ME, Hull HF, Aylward RB. 1999. Poliomyelitis eradication. Virus Res. 62:185-192. http://dx.doi.org /10.1016/S0168-1702(99)00044-1.
2. Mangal TD, Aylward RB, Grassly NC. 2013. The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting. Am. J. Epidemiol. 178:1579-1587. http://dx.doi.org/10.1093/aje/kwt203.
3. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. 2007. Vaccination against polio should not be stopped. Nat. Rev. Microbiol. 5:952-958. http: //dx.doi.org/10.1038/nrmicro1769.
4. Minor PD, Muir P. 2009. Enteroviruses, p 601-624. In Zuckerman AJ (ed), Principles and practice of clinical virology. John Wiley & Sons, Inc, New York, NY.
5. Minor PD. 2012. The polio-eradication programme and issues of the end game. J. Gen. Virol. 93(Pt 3):457-474. http://dx.doi.org/10.1099/vir.0.036988-0.
6. Estivariz CF, Pallansch MA, Anand A, Wassilak SG, Sutter RW, Wenger JD, Orenstein WA. 2013. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr. Opin. Virol. 3:309-315. http://dx.doi.org/10.1016/j.coviro.2013.05.007.
7. Minor P. 2009. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27:2649-2652. http://dx.doi.org/10.1016/j.vaccine.2009.02.071.
8. Ehrenfeld E, Glass RI, Agol VI, Chumakov K, Dowdle W, John TJ, Katz SL, Miller M, Breman JG, Modlin J, Wright P. 2008. Immunization against poliomyelitis: moving forward. Lancet 371:1385-1387. http://dx.doi.org/10.1016/S0140-6736(08)60597-8.
9. Fine PE, Oblapenko G, Sutter RW. 2004. Polio control after certification: major issues outstanding. Bull. World Health Organ. 82:47-52.
10. Fine PE, Ritchie S. 2006. Perspective: determinants of the severity of poliovirus outbreaks in the post eradication era. Risk Anal. 26:1533-1540. http://dx.doi.org/10.1111/j.1539-6924.2006.00855.x.
11. Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr, Alexander J, Jafari H, Cochi SL. 2008. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am. J. Public Health 98:1322-1330. http://dx.doi.org/10.2105/AJPH.2007.122192.
12. Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ, Bazeley PL. 1954. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Public Health Nations Health 44:563-570. http://dx.doi.org/10.2105/AJPH.44.5.563.
13. Ferguson M, Wood DJ, Minor PD. 1993. Antigenic structure of poliovirus in inactivated vaccines. J. Gen. Virol. 74(Pt 4):685-690. http://dx.doi.org/10.1099/0022-1317-74-4-685.
14. Martin J, Crossland G, Wood DJ, Minor PD. 2003. Characterization of formaldehyde-inactivated poliovirus preparations made from liveattenuated strains. J. Gen. Virol. 84(Pt 7):1781-1788. http://dx.doi.org/10.1099/vir.0.19088-0.
15. Rieder E, Wimmer E. 2002. Cellular receptors of picornaviruses: an overview, p 61-70. In Semler BL, Wimmer E (ed), Molecular biology of picornaviruses. ASM Press, Washington, DC.
16. Solecki D, Gromeier M, Harber J, Bernhardt G, Wimmer E. 1998. Poliovirus and its cellular receptor: a molecular genetic dissection of a virus/receptor affinity interaction. J. Mol. Recognit. 11:2-9. http://dx.doi.org/10.1002/(SICI)1099-1352(199812)11:1/6<2::AID-JMR380>3.0.CO;2-D.
17. Colston E, Racaniello VR. 1994. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J. 13:5855-5862.
18. Colston EM, Racaniello VR. 1995. Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition. J. Virol. 69:4823-4829.
19. Liao S, Racaniello V. 1997. Allele-specific adaptation of poliovirus VP1 B-C loop variants to mutant cell receptors. J. Virol. 71:9770-9777.
20. Belnap DM, McDermott BM, Jr, Filman DJ, Cheng N, Trus BL, Zuccola HJ, Racaniello VR, Hogle JM, Steven AC. 2000. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl. Acad. Sci. U. S. A. 97:73-78. http://dx.doi.org/10.1073/pnas.97.1.73.
21. He Y, Bowman VD, Mueller S, Bator CM, Bella J, Peng X, Baker TS, Wimmer E, Kuhn RJ, Rossmann MG. 2000. Interaction of the poliovirus receptor with poliovirus. Proc. Natl. Acad. Sci. U. S. A. 97:79-84. http: //dx.doi.org/10.1073/pnas.97.1.79.
22. Xing L, Tjarnlund K, Lindqvist B, Kaplan GG, Feigelstock D, Cheng RH, Casasnovas JM. 2000. Distinct cellular receptor interactions in poliovirus and rhinoviruses. EMBO J. 19:1207-1216. http://dx.doi.org/10.1093/emboj/19.6.1207.
23. Mendelsohn CL, Wimmer E, Racainiello VR. 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855-865. http: //dx.doi.org/10.1016/0092-8674(89)90690-9.
24. Tuthill TJ, Groppelli E, Hogle JM, Rowlands DJ. 2010. Picornaviruses. Curr. Top. Microbiol. Immunol. 343:43-89. http://dx.doi.org/10.1007 /82_2010_37.
25. Fricks CE, Hogle JM. 1990. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J. Virol. 64:1934-1945.
26. Tuthill TJ, Bubeck D, Rowlands DJ, Hogle JM. 2006. Characterization of early steps in the poliovirus infection process: receptor-decorated liposomes induce conversion of the virus to membrane-anchored entryintermediate particles. J. Virol. 80:172-180. http://dx.doi.org/10.1128/JVI.80.1.172-180.2006.
27. Breindl M. 1971. The structure of heated poliovirus particles. J. Gen. Virol. 11:147-156. http://dx.doi.org/10.1099/0022-1317-11-3-147.
28. Fenwick ML, Cooper PD. 1962. Early interactions between poliovirus and ERK cells: some observations on the nature and significance of the rejected particles. Virology 18:212-223. http://dx.doi.org/10.1016/0042-6822(62)90007-7.
29. Joklik WK, Darnell JE, Jr. 1961. The adsorption and early fate of purified poliovirus in HeLa cells. Virology 13:439-447. http://dx.doi.org/10.1016 /0042-6822(61)90275-6.
30. Curry S, Chow M, Hogle JM. 1996. The poliovirus 135S particle is infectious. J. Virol. 70:7125-7131.
31. Bostina M, Levy H, Filman DJ, Hogle JM. 2011. Poliovirus RNA is released from the capsid near a twofold symmetry axis. J. Virol. 85:776-783. http://dx.doi.org/10.1128/JVI.00531-10.
32. Levy HC, Bostina M, Filman DJ, Hogle JM. 2010. Catching a virus in the act of RNA release: a novel poliovirus uncoating intermediate characterized by cryo-electron microscopy. J. Virol. 84:4426-4441. http://dx.doi.org/10.1128/JVI.02393-09.
33. Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. 2007. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 25:7041-7046.
34. Rezapkin G, Martin J, Chumakov K. 2005. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals 33:29-39. http://dx.doi.org/10.1016/j.biologicals.2004.11.001.
35. Martin J. 2011. Detection and characterization of polioviruses, p 233-256. In Stephenson JR, Warnes A (ed), Diagnostic virology protocols. Humana Press, New York, NY.
36. Beale AJ, Mason PJ. 1962. The measurement of the D-antigen in poliovirus preparations. J. Hyg. 60:113-121. http://dx.doi.org/10.1017 /S002217240003936X.
37. Singer C, Knauert F, Bushar G, Klutch M, Lundquist R, Quinnan GV, Jr. 1989. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J. Biol. Stand. 17:137-150. http://dx.doi.org/10.1016/0092-1157(89)90004-8.
38. Sawyer LA, Wood D, Ferguson M, Crainic R, Beuvery EC, McInnis J, Albrecht P. 1997. Potency of wild-type or Sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclo-nal antibiotics specific for each antigenic site. Biologicals 25:299-306. http://dx.doi.org/10.1006/biol.1997.0100.
39. Fuchs F, Minor P, Daas A, Milne C. 2003. Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay. Pharmeuropa Bio. 2003:23-50.
40. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. 2006. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80:9687-9696. http://dx.doi.org/10.1128/JVI.00738-06.
41. Jonsson N, Gullberg M, Israelsson S, Lindberg AM. 2009. A rapid and efficient method for studies of virus interaction at the host cell surface using enteroviruses and real-time PCR. Virol. J. 6:217. http://dx.doi.org /10.1186/1743-422X-6-217.
42. Rozenand S, Skaletsky HJ. 2000. Primer3 on the WWW for general users and for biologist programmers, p 365-386. In Krawetz S, Misener S (ed), Bioinformatics methods and protocols: methods in molecular biology, Humana Press, New York, NY.
43. Macadam AJ, Pollard SR, Ferguson G, Dunn G, Skuce R, Almond JW, Minor PD. 1991. The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181:451-458. http://dx.doi.org/10.1016/0042-6822(91)90877-E.
44. Gonzalez G, Pfannes L, Brazas R, Striker R. 2007. Selection of an optimal RNA transfection reagent and comparison to electroporation for the delivery of viral RNA. J. Virol. Methods 145:14-21. http://dx.doi.org/10.1016/j.jviromet.2007.04.013.
45. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N. 2014. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 370:818-828. http://dx.doi.org/10.1056/NEJMoa1304923.
46. Fiore AE, Feinstone SM, Bell BP. 2008. Hepatitis A vaccines, p 177-203. In Plotkin S, Orenstein WA, Offit PA (ed), Vaccines. Saunders/Elsevier, Philadelphia, PA.
47. Bridges CB, Katz JM, Levanowski RA, Cox NJ. 2008. Inactivated influenza vaccines, p 259-290. In Plotkin S, Orenstein WA, Offit PA (ed), Vaccines. Saunders/Elsevier, Philadelphia, PA.
48. Lentz KN, Smith AD, Geisler SC, Cox S, Buontempo P, Skelton A, DeMartino J, Rozhon E, Schwartz J, Girijavallabhan V, O'Connell J, Arnold E. 1997. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure 5:961-978. http://dx.doi.org/10.1016/S0969-2126(97)00249-9.
49. Page GS, Mosser AG, Hogle JM, Filman DJ, Rueckert RR, Chow M. 1988. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J. Virol. 62:1781-1794.
50. Filman DJ, Syed R, Chow M, Macadam AJ, Minor PD, Hogle JM. 1989. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J. 8:1567-1579.
51. Hogle JM. 2002. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu. Rev. Microbiol. 56:677-702. http://dx.doi.org /10.1146/annurev.micro.56.012302.160757.
52. Hogle JM, Chow M, Filman DJ. 1985. Three-dimensional structure of poliovirus at 2.9-Å resolution. Science 229:1358-1365. http://dx.doi.org /10.1126/science.2994218.
53. Twomey T, Newman J, Burrage T, Piatti P, Lubroth J, Brown F. 1995. Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Vaccine 13:1603-1610.
54. Lin J, Cheng N, Hogle JM, Steven AC, Belnap DM. 2013. Conformational shift of a major poliovirus antigen confirmed by immuno-cryogenic electron microscopy. J. Immunol. 191:884-891. http://dx.doi.org/10.4049/jimmunol.1202014.
55. Martin-Acebes MA, Vazquez-Calvo A, Gonzalez-Magaldi M, Sobrino F. 2011. Foot-and-mouth disease virus particles inactivated with binary ethylenimine are efficiently internalized into cultured cells. Vaccine 29:9655-9662. http://dx.doi.org/10.1016/j.vaccine.2011.10.031.
56. Duque H, Marshall RL, Israel BA, Letchworth GJ. 1989. Effects of formalin inactivation on bovine herpesvirus-1 glycoproteins and antibody response elicited by formalin-inactivated vaccines in rabbits. Vaccine 7:513-520.
57. King DJ. 1991. Evaluation of different methods of inactivation of Newcastle disease virus and avian influenza virus in egg fluids and serum. Avian Dis. 35:505-514. http://dx.doi.org/10.2307/1591214.
58. Furuya Y, Regner M, Lobigs M, Koskinen A, Mullbacher A, Alsharifi M. 2010. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations. J. Gen. Virol. 91(Pt 6):1450-1460. http://dx.doi.org/10.1099/vir.0.018168-0.
59. Blackburn NK, Besselaar TG. 1991. A study of the effect of chemical inactivants on the epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies. J. Virol. Methods 33:367-374. http://dx.doi.org /10.1016/0166-0934(91)90036-Y.
60. Dedhia P, Tarale S, Dhongde G, Khadapkar R, Das B. 2007. Evaluation ofDNAextraction methods and real-time PCR optimization on formalinfixed paraffin-embedded tissues. Asian Pacific J. Cancer Prev. 8:55-59.
61. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. 1999. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 27:4436-4443. http://dx.doi.org/10.1093/nar/27.22.4436.
62. Budowsky EI, Friedman EA, Zheleznova NV, Noskov FS. 1991. Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone. Vaccine 9:398-402.
63. Frazatti-Gallina NM, Mourao-Fuches RM, Paoli RL, Silva ML, Miyaki C, Valentini EJ, Raw I, Higashi HG. 2004. Vero cell rabies vaccine produced using serum-free medium. Vaccine 23:511-517. http://dx.doi.org/10.1016/j.vaccine.2004.06.014.
64. Rowlands DJ, Minor PD. 2010. Vaccine strategies, p 431-447. In Ehrenfeld E, Domingo E, Roos RP (ed), The picornaviruses. ASM Press, Washington, DC.